October 29, 2019: EicOsis Announces SBIR Grant Award from NCI/NIH The National Institute of Health has awarded a Small Business Innovation Research (SBIR) grant from the National Cancer Institute to EicOsis, LLC to support preclinical testing of soluble epoxide inhibitors for treating neuropathic pain associated with chemotherapy drugs.
July 7, 2015: Key mechanism that causes neuropathic pain found A biological process called endoplasmic reticulum stress appears to play a key role in causing neuropathic pain, according to a new study. The discovery could eventually lead to new therapeutics for controlling chronic pain associated with trauma, diabetes, shingles, multiple sclerosis or other conditions that cause nerve damage.
September 1, 2006: Pest Control Research Leads To Pain Control Discovery A newly discovered enzyme inhibitor, identified by researchers originally looking for biological pest controls, may lead to pain relief for sufferers of arthritis and other inflammatory diseases, say researchers at the University of California, Davis. The finding, hailed by a noted inflammatory disease expert "as the most important discovery in inflammation in more than a decade," may also reduce side effects associated with the painkiller, Vioxx.
The National Institute on Drug Abuse (NIDA) has awarded a grant to EicOsis LLC as part of the NIH initiative Helping to End Addiction Long-Term (HEAL Initiative) to support human clinical trials of a novel compound that has been found effective for the treatment of pain in preclinical animal studies.